Journal: Neuron

Article Title: Actin is crucial for all kinetically distinguishable forms of endocytosis at synapses

doi: 10.1016/j.neuron.2016.10.014

Figure Lengend Snippet: (A) Western blot of β-actin, AP-2, Clathrin heavy chain (CLT), dynamin (DMN) and GAPDH (Glyceraldehyde 3-phosphate dehydrogenase, loading control) from ActbLoxP/LoxP hippocampal cultures transfected with nothing (Ctrl) or with lentivirus containing a Cre enzyme (Actb−/−).

Article Snippet: Equal amounts of proteins, determined by BCA protein assay (Thermo Scientific), were loaded onto SDS-PAGE gel and immunoblotted using antibodies against β-actin (1: 1000, Abcam, Cambridge, MA), γ-actin (mAB1-37; 1:500), AP-2 (1:100, Thermo Scientific), clathrin heavy chain (1:1,000, BD Bioscience, San Jose, CA), dynamin (1:1,000; BD Bioscience) and GAPDH (1:2,000; Sigma).

Techniques: Western Blot, Transfection

Journal: Cell death discovery

Article Title: IFNγ regulates ferroptosis in KFs by inhibiting the expression of SPOCD1 through DNMT3A.

doi: 10.1038/s41420-024-02257-z

Figure Lengend Snippet: Fig. 4 IFNγ could regulate the expression of DNMT3A in keloids. A The string of protein-protein interactions. B Immunohistochemical staining for IFNγ in normal skin and keloid. C The western blotting results of IFNγ in normal skin and keloid. D The western blotting results of KFs after treated with oe-DNMT1, oe-DNMT3A and oe-DNMT3B for 24 h. E Gene expression of KFs after treated with oe-DNMT1, oe-DNMT3A and oe-DNMT3B for 24 h. F The western blotting results of KFs after treated with si-DNMT1, si-DNMT3A and si-DNMT3B for 24 h. G Gene expression of KFs after treated with si-DNMT1, si-DNMT3A and si-DNMT3B for 24 h. H The western blotting results of IFNγ and DNMT3A after treated with si-IFNγ or oe-IFNγ. Bar=100 μm. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The primary antibodies included rabbit antibodies against β-actin (proteintech, 1:1,000), SPOCD1 (proteintech, 1:5,000), IFNγ (proteintech, 1:1,000), GPX4 (proteintech, 1:10,000), GSH (proteintech, 1:1,000), SLC7A11 (proteintech, 1:1,000), SLC3A2 (proteintech, 1:1,000), DNMT1 (proteintech, 1:1,000), DNMT3A (proteintech, 1:1,000), and DNMT3B (proteintech, 1:2,000).

Techniques: Expressing, Protein-Protein interactions, Immunohistochemical staining, Staining, Western Blot, Gene Expression

Journal: PLoS ONE

Article Title: Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells

doi: 10.1371/journal.pone.0136893

Figure Lengend Snippet: A) Normalized DNMT activity in control, CPR cells as well as cells that received the EGFR inhibitor Erlotinib only or Erlotinib + cisplatin during the cisplatin resistance paradigm, n = 4. One-way ANOVA followed by Dunnet’s post hoc showed that Erlotinib co-treatment with cisplatin in the cisplatin resistance paradigm attenuated the increase in DNMT activity observed in CPR cells. B) Normalized percent 5-methylcytosine (5mC) or DNA global methylation for control, CPR cells as well as cells that received the EGFR inhibitor Erlotinib only or Erlotinib + cisplatin during the cisplatin resistance paradigm, n = 4–6. One way ANOVA followed by Tukey’s post hoc revealed a significant increase in global DNA methylation in CPR cells, but not in cells that received Erlotinib *p<0.05.

Article Snippet: Total DNMT activity was determined using 20 μg total protein and the EpiQuik DNA Methyltransferase (DNMT) Activity/Inhibition Assay Kit (Epigentek) as recommended by the manufacturer.

Techniques: Activity Assay, Control, Methylation, DNA Methylation Assay